As the world moves forward shaped by the COVID-19 pandemic, so many of us crave a “return to normal.” At Gore, we too are eager for our Associates to rejoin their colleagues who have remained in our plants to produce essential materials and products.

FLAGSTAFF, Ariz. (December 11, 2013) — W. L. Gore & Associates (Gore) today announced that the Food and Drug Administration (FDA) has granted indication for the GORE® VIABAHN® Endoprosthesis to treat stenosis or thrombotic occlusion at the venous anastomosis of synthetic arteriovenous access (AV access) grafts.

This study aims to compare the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease with the goal of informing practice guidelines around which modality is best suited for patients with this condition.

FLAGSTAFF, Ariz. (August 19, 2021) — W. L. Gore & Associates (Gore), today announced that five-year results of the U.S. prospective, multicenter study (N = 63) of endovascular repair of iliac aneurysms using the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) were presented at the 2021 Society for Vascular Surgery Annual Meeting. Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.

Gore, a global material science company dedicated to transforming industries and improving lives, announce the acquisition of InnAVasc Medical, Inc., a privately held medical technology company focused on advancing care for patients with end stage renal disease who utilize graft circuits for dialysis treatment.

The first patient implant in the ARISE II Pivotal Study evaluation of the GORE® Ascending Stent Graft represents a major milestone in the development of endovascular treatment of the ascending aorta.

FIRST U.S. PATIENT ENROLLED IN GORE® VIAFORT VASCULAR STENT ILIOFEMORAL PIVOTAL STUDY

First U.S. patient enrolled in GORE® VIAFORT Vascular Stent pivotal study.